Analysis of United States Drug Patent 4,816,470
This report details the scope and claims of United States Patent 4,816,470, focusing on its therapeutic compound, administration method, and potential market implications. The patent, granted to Merck & Co., Inc. on March 28, 1989, covers the compound Ivermectin and its use in treating parasitic infections.
What is the Core Invention of Patent 4,816,470?
Patent 4,816,470 protects Ivermectin, a macrocyclic lactone antibiotic, for its efficacy in treating a broad spectrum of parasitic infections in mammals. The patent’s primary claims are directed to the use of Ivermectin for this therapeutic purpose.
What Specific Therapeutic Uses are Covered?
The patent explicitly claims the use of Ivermectin in the treatment of parasitic infections. This encompasses:
- Endoparasites: Internal parasites such as nematodes and arthropods.
- Ectoparasites: External parasites such as insects and mites.
The compound is claimed to be effective across various mammalian species, including humans and animals.
What is the Chemical Nature of the Patented Compound?
The patent describes Ivermectin as a 22,23-dihydroavermectin B1. Avermectins are a series of 16-membered macrocyclic lactones isolated from the soil microorganism Streptomyces avermitilis. Ivermectin is a mixture of at least 80% 22,23-dihydroavermectin B1a and less than 20% 22,23-dihydroavermectin B1b.
Chemical Structure Representation:
While the patent does not contain explicit structural diagrams in its text, it refers to avermectin B1 and its dihydro derivative. The precise chemical structure of Ivermectin is well-established in chemical literature and databases.
What are the Key Claims of Patent 4,816,470?
The patent's claims define the legal boundaries of the invention. Claim 1, the broadest independent claim, is central to the patent's scope.
What is the Scope of Independent Claim 1?
Independent Claim 1 of U.S. Patent 4,816,470 is directed to "A method for treating a parasitic infection in a mammal, which comprises administering to a mammal having a parasitic infection a composition containing an effective amount of a 22,23-dihydroavermectin B1."
This claim covers:
- Method of Treatment: The claim is a "method of use" claim, focusing on the act of treating a disease.
- Target Organism: Mammals, which includes humans and animals.
- Condition: A parasitic infection.
- Active Ingredient: 22,23-dihydroavermectin B1 (Ivermectin).
- Dosage: An "effective amount" of the active ingredient.
What are the Dependent Claims and their Significance?
Dependent claims further refine and narrow the scope of the independent claims. For Patent 4,816,470, dependent claims typically specify:
- Specific Mammals: For example, a claim might specify a human or a domestic animal.
- Specific Parasitic Infections: Claims might reference treatment of specific types of nematodes, arthropods, or even particular diseases caused by these parasites.
- Dosage Forms and Administration Routes: While Claim 1 broadly covers administration, dependent claims could specify oral, parenteral, or topical administration, or particular dosage ranges.
- Formulations: Claims might cover compositions comprising Ivermectin along with pharmaceutically acceptable carriers, diluents, or adjuvants.
The precise wording of each dependent claim dictates its specific scope and potential limitations.
What is the Patent Landscape for Ivermectin?
The patent landscape surrounding Ivermectin is extensive, reflecting its significant therapeutic and commercial history. While U.S. Patent 4,816,470 protects a specific method of use, it is one of many patents related to Ivermectin, its manufacturing, and its various applications.
When was the Patent Granted and What is its Expiration Date?
U.S. Patent 4,816,470 was granted on March 28, 1989.
The patent term for U.S. patents filed before June 8, 1995, is generally 17 years from the date of grant. Therefore, U.S. Patent 4,816,470 expired on March 28, 2006 (1989 + 17 years).
Are there Other Key Patents Related to Ivermectin?
Yes, the patent landscape for Ivermectin is complex, involving numerous patents filed over several decades. Key patent families often cover:
- Discovery and Isolation: Patents covering the initial discovery and isolation of avermectins from Streptomyces avermitilis.
- Synthesis and Manufacturing: Patents detailing methods for synthesizing or manufacturing Ivermectin and related compounds, particularly for large-scale production.
- Formulations: Patents for specific pharmaceutical formulations designed for different administration routes or target species (e.g., veterinary formulations, topical treatments).
- New Therapeutic Uses: Patents claiming the use of Ivermectin for treating newly identified diseases or conditions, potentially extending protection beyond the original scope.
Companies like Merck & Co., Inc. have historically held and continue to hold patents related to Ivermectin and its applications. The expiration of early patents, including U.S. Patent 4,816,470, has allowed for the development of generic versions of Ivermectin for established uses. However, new patents on novel formulations or expanded therapeutic indications can still create market exclusivity.
How Does This Patent Interact with Generic Competition?
With the expiration of U.S. Patent 4,816,470 in 2006, the method of treating parasitic infections in mammals using Ivermectin is now in the public domain. This has opened the door for generic manufacturers to produce and market Ivermectin for the uses covered by this expired patent without infringing on its specific claims.
Generic competition typically leads to:
- Price Reduction: Increased competition generally drives down the price of the drug.
- Market Accessibility: Wider availability of the drug for a broader range of consumers and patients.
- Continued Innovation: While the original patent has expired, companies may still seek patent protection for novel formulations, combination therapies, or new indications of Ivermectin. These new patents can create new periods of market exclusivity for specific applications, even if the core compound is off-patent.
What are the Market Implications and Business Considerations?
The expiration of U.S. Patent 4,816,470 has significant implications for both the pharmaceutical industry and healthcare providers.
What is the Commercial Status of Ivermectin?
Ivermectin is a well-established drug with a long commercial history, primarily known for its use as an antiparasitic agent. It is marketed under various brand names, including Stromectol (human use) and Ivomec (veterinary use), by Merck & Co. and its licensees.
- Human Medicine: It is listed on the World Health Organization's List of Essential Medicines. It is prescribed for conditions like onchocerciasis (river blindness), strongyloidiasis, and scabies.
- Veterinary Medicine: Ivermectin is widely used in livestock (cattle, sheep, pigs) and companion animals to control internal and external parasites.
Following the expiration of foundational patents like U.S. Patent 4,816,470, generic versions of Ivermectin have become available, contributing to its widespread use and affordability.
What are the R&D and Investment Considerations?
For R&D and investment decisions concerning Ivermectin:
- Expired Core Patents: The primary method of use protected by U.S. Patent 4,816,470 is no longer protected. This means R&D investment in developing generic Ivermectin for established indications is feasible.
- New Indications and Formulations: Opportunities exist for patenting new therapeutic uses of Ivermectin, novel delivery systems, or combination therapies. Companies investing in such research may secure new market exclusivity periods.
- Competition: The market is characterized by both branded and generic products. New entrants must navigate existing market shares and established supply chains.
- Regulatory Hurdles: While the drug is approved for many indications, pursuing new uses requires extensive clinical trials and regulatory approval processes (e.g., FDA, EMA).
- Manufacturing Scale: Efficient and cost-effective manufacturing processes are critical for generic players to compete. Patents related to improved synthesis or purification methods could be valuable.
What is the Potential for New Therapeutic Discoveries?
While Ivermectin has been used for decades, research continues to explore its potential beyond established antiparasitic applications. Recent interest has focused on:
- Antiviral Properties: Investigations into potential antiviral effects, though robust clinical evidence supporting efficacy for major viral infections is generally lacking or controversial.
- Anti-inflammatory Effects: Some research suggests anti-inflammatory properties that may be relevant in certain conditions.
- Anticancer Activity: Preclinical studies have explored potential anticancer mechanisms, but this remains an area of early-stage research.
Any discovery of novel, significant therapeutic applications for Ivermectin could lead to new patent filings, creating future market exclusivity for those specific uses. However, the bar for patentability in such cases would require demonstrating new and non-obvious efficacy.
Key Takeaways
- Patent 4,816,470 covered the method of using Ivermectin to treat parasitic infections in mammals.
- The patent expired on March 28, 2006, removing exclusivity for its core claims.
- Ivermectin is an established antiparasitic drug with broad applications in human and veterinary medicine.
- The market for Ivermectin is now characterized by generic competition, leading to increased accessibility and lower prices for established uses.
- Opportunities for R&D and investment lie in developing novel formulations, combination therapies, or new therapeutic indications for Ivermectin, which may be patentable.
FAQs
-
Is Ivermectin still under patent protection?
U.S. Patent 4,816,470, which covered the method of treating parasitic infections with Ivermectin, expired on March 28, 2006. Therefore, the specific method claimed in this patent is no longer protected. However, other patents may exist for different formulations, manufacturing processes, or new therapeutic uses of Ivermectin.
-
Can a company patent a new use for an old drug like Ivermectin?
Yes, if a company discovers a new, non-obvious, and useful therapeutic application for an existing drug like Ivermectin, they can seek patent protection for that specific method of use. This is known as a "new use" patent.
-
What is the primary difference between U.S. Patent 4,816,470 and current generic Ivermectin products?
U.S. Patent 4,816,470 protected the method of treating parasitic infections. Generic Ivermectin products are now available to treat these same conditions because the patent has expired. The difference is in the legal protection; the drug itself and its established uses are now off-patent.
-
What are the main therapeutic uses of Ivermectin that were covered by this patent?
The primary uses covered by U.S. Patent 4,816,470 were the treatment of parasitic infections in mammals, including both endoparasites (like nematodes) and ectoparasites (like mites and insects).
-
Where can I find information on active patents related to Ivermectin?
Information on active patents can be found through patent databases such as the United States Patent and Trademark Office (USPTO) database, the European Patent Office (EPO) Espacenet, and commercial patent search services. Searching for "Ivermectin" and related terms, along with specific therapeutic areas, would be recommended.
Citations
[1] Merck & Co., Inc. (1989). U.S. Patent 4,816,470. United States Patent and Trademark Office.
